These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33042821)

  • 1. Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population.
    Qi Y; Liao D; Mei D; Zhang Y; Liu Y
    Front Oncol; 2020; 10():1752. PubMed ID: 33042821
    [No Abstract]   [Full Text] [Related]  

  • 2. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
    Bartlett EK; Flynn JR; Panageas KS; Ferraro RA; Sta Cruz JM; Postow MA; Coit DG; Ariyan CE
    Cancer; 2020 Jan; 126(1):76-85. PubMed ID: 31584709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population.
    Wang C; Liu S; Li X; Cui K; Zhang W; Du Y
    Front Oncol; 2023; 13():1118301. PubMed ID: 37152022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
    Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
    Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy.
    Chen L; Zuo Y; Zhu L; Zhang Y; Li S; Ma F; Han Y; Song H; Xue Y
    Onco Targets Ther; 2017; 10():2569-2580. PubMed ID: 28553122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy.
    Gao Y; Zhang Z; Li Y; Chen S; Lu J; Wu L; Ma Z; Hu Y; Zhang G
    Front Oncol; 2022; 12():834564. PubMed ID: 35494073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer.
    Wang X; Teng F; Kong L; Yu J
    Onco Targets Ther; 2016; 9():5761-5770. PubMed ID: 27703374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Liu B; Kotenko S; Li W
    Medicine (Baltimore); 2022 Aug; 101(32):e29536. PubMed ID: 35960066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
    Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
    J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
    [No Abstract]   [Full Text] [Related]  

  • 14. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 16. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.
    Reddy AV; Hill CS; Sehgal S; Zheng L; He J; Laheru DA; Jesus-Acosta A; Herman JM; Meyer J; Narang AK
    Radiat Oncol J; 2022 Jun; 40(2):111-119. PubMed ID: 35796114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-
    Bai X; Dai J; Li C; Cui C; Mao L; Wei X; Sheng X; Chi Z; Yan X; Tang B; Lian B; Wang X; Zhou L; Li S; Kong Y; Qi Z; Xu H; Duan R; Guo J; Si L
    Front Oncol; 2021; 11():639085. PubMed ID: 34094921
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis.
    Zhan H; Ma JY; Jian QC
    Clin Chim Acta; 2018 Sep; 484():136-140. PubMed ID: 29856976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
    Lalani AA; Xie W; Martini DJ; Steinharter JA; Norton CK; Krajewski KM; Duquette A; Bossé D; Bellmunt J; Van Allen EM; McGregor BA; Creighton CJ; Harshman LC; Choueiri TK
    J Immunother Cancer; 2018 Jan; 6(1):5. PubMed ID: 29353553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.